Inhibition of clinical isolates of human cytomegalovirus and varicella zoster virus by PNU-183792, a 4-oxo-dihydroquinoline

J Med Virol. 2002 Oct;68(2):234-6. doi: 10.1002/jmv.10193.

Abstract

The susceptibility of human cytomegalovirus (CMV) and varicella zoster virus (VZV) clinical isolates to PNU-183792, a 4-oxo-dihydroquinoline, was examined. The antiviral potency of PNU-183792, a non-nucleoside inhibitor, was compared to the licensed nucleoside inhibitors ganciclovir and acyclovir using plaque reduction and virus yield reduction assays. PNU-183792 was as potent against CMV as ganciclovir and was superior in potency to acyclovir against VZV. PNU-183792 represents a new class of non-nucleoside inhibitors of human herpesviruses.

Publication types

  • Comparative Study

MeSH terms

  • Acyclovir / pharmacology
  • Antiviral Agents / pharmacology*
  • Cell Line
  • Cytomegalovirus / drug effects*
  • Cytomegalovirus / growth & development
  • Cytomegalovirus / isolation & purification
  • Cytomegalovirus / physiology
  • Ganciclovir / pharmacology
  • Herpesvirus 3, Human / drug effects*
  • Herpesvirus 3, Human / growth & development
  • Herpesvirus 3, Human / isolation & purification
  • Herpesvirus 3, Human / physiology
  • Humans
  • In Vitro Techniques
  • Quinolines / pharmacology*
  • Viral Plaque Assay
  • Virus Replication / drug effects

Substances

  • Antiviral Agents
  • PNU183792
  • Quinolines
  • Ganciclovir
  • Acyclovir